BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

4:43 PM
 | 
May 15, 2018
 |  BioCentury  |  Finance

Single Celsius

Third Rock launched Celsius to apply single-cell genomics to drug development

After identifying its first targets, Third Rock Ventures newco Celsius Therapeutics emerged from stealth with a $65 million series A round to apply single-cell genomics techniques to drug development for autoimmune diseases and cancer.

GV, Heritage Provider Network, Casdin Capital, Alexandria Venture Investments and undisclosed other investors also participated in the round.

Third Rock’s Christoph Lengauer, who serves as the newco’s president, told BioCentury Celsius is the first therapeutics company to leverage single-cell genomics rather than the traditional genomic sequencing approach, which he said is limited by low resolution given that traditional...

Read the full 448 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >